Weight-loss drugs reshape pharma, generics, and DTC telehealth

A new wave of GLP-1 obesity and diabetes drugs is fueling massive growth across pharma and digital health, from Eli Lilly’s once-daily oral rival to Ozempic to telehealth platforms like Hims & Hers racing to capture demand. While Indian players such as Sun Pharma, Lupin, and Cipla prepare for a global GLP-1 opportunity, semaglutide’s U.S. patent protection likely blocks true generic competition until around 2030–2031, preserving high prices and margins. Direct-to-consumer telehealth models are being scrutinized over how they prescribe and market GLP-1s, underscoring the tension between rapid virtual care expansion, regulatory oversight, and long-term questions about affordability and access.